Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for treating metastatic tumor cells of epithelial tissue origin or placental cytotrophoblast cells of a subject comprising administrating to said subject an antisense molecule, said antisense molecule comprising a nucleotide sequence which ~~is complementary~~hybridizes to an RNA sequence of a ~~protease activated receptor (PAR)~~thrombin receptor, thereby interfering with the process of mRNA translation into protein.

2-4. (Canceled)

5. (Currently Amended) A method according to claim ~~4~~1 wherein said epithelial tissue is selected from the group consisting of breast, esophagus, kidney, prostate, ovary, melanoma and bladder.

6. (Currently Amended) A method according to claim 1 wherein said antisense molecule has the sequence appearing in ~~Fig. 2~~SEQ ID NO: 7.

7. (Canceled)

8. (Canceled)

9. (Currently Amended) An expression vector comprising an antisense molecule comprising a nucleotide sequence which ~~is complementary~~hybridizes to an RNA sequence of a ~~protease activated~~thrombin receptor ~~(PAR)~~ protein, wherein said nucleotide sequence consists of between 250 and 600 base pairs.

10. (Currently Amended) A pharmaceutical composition comprising an active factor and a pharmaceutically acceptable carrier, said active factor being an antisense molecule comprising a nucleotide sequence which ~~is complementary to~~ hybridizes to an RNA sequence of a ~~protease activated receptor (PAR)~~thrombin receptor, thereby interfering with the process of mRNA translation into protein.

11. (Original) A pharmaceutical composition according to claim 10 for the treatment of metastatic tumor cells.

12. (Canceled)

13. (Canceled)

14. (Original) A pharmaceutical composition according to claim 11 wherein said tumor cell is of epithelial tissue origin.

15. (Original) A pharmaceutical composition according to claim 14 wherein said epithelial tissue is selected from the group consisting of breast, esophagus, kidney, prostate, ovary, melanoma and bladder.

16. (Currently Amended) A pharmaceutical composition according to claim 10 wherein said antisense molecule has the sequence appearing in ~~Fig. 2~~SEQ ID NO: 7.

17. (Currently Amended) A method for the treatment of disorders involving the implantation of a placenta in a female subject comprising administrating to said subject an antisense molecule, said antisense molecule comprising a nucleotide sequence which ~~is complementary~~hybridizes to an RNA sequence of a ~~protease activated receptor (PAR)~~thrombin receptor, thereby interfering with the process of mRNA translation into protein.

18. (Previously Amended) A method according to claim 17 wherein said antisense molecule is administered to a trophoblast cell.

19. (Original) A pharmaceutical composition according to claim 10 for the treatment of disorders involving the implantation of a placenta in a female subject.

~~20~~. (New) An antisense molecule being SEQ ID NO: 7.

21. (New) A method according to claim 1, wherein said antisense molecule is an expression vector containing said nucleotide sequence in an antisense orientation.

22. (New) A method according to claim 21, wherein said nucleotide sequence has from 250 to 600 base pairs.

23. (New) The pharmaceutical composition according to claim 10, wherein said antisense molecule is an expression vector containing said nucleotide sequence in an antisense orientation.

24. (New) A pharmaceutical composition according to claim 23, wherein said nucleotide sequence has from 250 to 600 base pairs.

C1

25. (New) A method according to claim 17, wherein said antisense molecule is an expression vector containing said nucleotide sequence in an antisense orientation.

26. (New) A method according to claim 25, wherein said nucleotide sequence has from 250 to 600 base pairs.